Revlimid 25 mg hard capsules clinical trials
5 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
For: Multiple MyelomaBelgium · France - AuthorisedTherapeutic exploratory (Phase II)
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
This study looks at new ways to decide when to start a second treatment for certain types of lymphoma, using a blood test. It aims to see if this approach is safe and effective in helping patients.
For: Diffuse large B-cell lymphomas (DLBCL · Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL · High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
This study looks at a new treatment, idecabtagene vicleucel (bb2121), for multiple myeloma that has come back or not responded to previous treatments. It compares this new treatment to standard options to see if it works better and is safe for patients aged 18 and over.
Germany · Spain · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
This study is looking at a new treatment combination for a type of blood cancer called multiple myeloma, for people who aren't having a stem cell transplant. It compares a new four-drug treatment with a standard three-drug treatment to see if the new one works better.
For: Multiple MyelomaSpain · Netherlands · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as pre transplant INDUCTION and post transplant consolidation or continuous treatment with CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 cycles) without transplant, all followed by MAINTENANCE with LENALIDOMIDE (R) versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
This study looks at new ways to treat newly diagnosed multiple myeloma. It compares different drug combinations, with or without a stem cell transplant, followed by ongoing treatment to see which works best at keeping the cancer under control. It aims to find better treatments for patients.
For: NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANTItaly